KORRO

Korro Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 5, 2022

CAMBRIDGE, Mass., January 5, 2022 <u>Korro Bio, Inc.</u>, a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer and President, will present at the 40th Annual J.P. Morgan Healthcare Conference, taking place virtually January 10–13, 2022.

Presentation details:

Date: Tuesday, January 11, 2022 Time: 1:30 p.m. ET–1:55 p.m. ET

About Korro Bio, Inc.

Korro is an RNA editing company focused on discovery and development of a new class of precision genetic medicines. Korro's proprietary and modular platform, OPERATM, combines data-driven design with off-the-shelf chemistry and delivery to achieve highly selective RNA editing. This unique technology enables the functional benefits of gene therapy with a transient, repeated-administration regimen that permits pharmacologic titration of therapeutic efficacy and safety, in a cost-effective drug product. As a result, Korro's portfolio of innovative RNA therapies have the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is located in Cambridge, Mass. For more information, visit korrobio.com.

Investor Contact Vineet Agarwal vagarwal@korrobio.com

Media Contact Chris Railey Ten Bridge Communications <u>chris@tenbridgecommunications.com</u> M: +1 617-834-0936